Gastroparesis: A turning point in understanding and treatment

Madhusudan Grover, Gianrico Farrugia, Vincenzo Stanghellini

Research output: Contribution to journalArticle

Abstract

Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and 13C breath testing provide the most validated assessment of GE. The stagnant gastroparesis therapeutic landscape is likely to soon see significant changes. Relatively newer treatment strategies include antiemetics (aprepitant), prokinetics (prucalopride, relamorelin) and fundic relaxants (acotiamide, buspirone). Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting. Further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. This review highlights the clinical presentation, diagnosis, mechanisms and treatment advancements for gastroparesis.

Original languageEnglish (US)
JournalGut
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Gastroparesis
Gastric Emptying
prucalopride
aprepitant
Nausea
Vomiting
Interstitial Cells of Cajal
Buspirone
Enteric Nervous System
Therapeutics
Antiemetics
Natural History
Radionuclide Imaging
Abdominal Pain
Oxidative Stress
Animal Models
Morbidity
Delivery of Health Care
Biopsy
Wounds and Injuries

Keywords

  • Gastric Emptying
  • Gastroparesis
  • Interstitial Cells of Cajal
  • Macrophages
  • Prokinetic Agent

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Gastroparesis : A turning point in understanding and treatment. / Grover, Madhusudan; Farrugia, Gianrico; Stanghellini, Vincenzo.

In: Gut, 01.01.2019.

Research output: Contribution to journalArticle

@article{8939190b8ff540098299624c14496aeb,
title = "Gastroparesis: A turning point in understanding and treatment",
abstract = "Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and 13C breath testing provide the most validated assessment of GE. The stagnant gastroparesis therapeutic landscape is likely to soon see significant changes. Relatively newer treatment strategies include antiemetics (aprepitant), prokinetics (prucalopride, relamorelin) and fundic relaxants (acotiamide, buspirone). Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting. Further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. This review highlights the clinical presentation, diagnosis, mechanisms and treatment advancements for gastroparesis.",
keywords = "Gastric Emptying, Gastroparesis, Interstitial Cells of Cajal, Macrophages, Prokinetic Agent",
author = "Madhusudan Grover and Gianrico Farrugia and Vincenzo Stanghellini",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/gutjnl-2019-318712",
language = "English (US)",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Gastroparesis

T2 - A turning point in understanding and treatment

AU - Grover, Madhusudan

AU - Farrugia, Gianrico

AU - Stanghellini, Vincenzo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and 13C breath testing provide the most validated assessment of GE. The stagnant gastroparesis therapeutic landscape is likely to soon see significant changes. Relatively newer treatment strategies include antiemetics (aprepitant), prokinetics (prucalopride, relamorelin) and fundic relaxants (acotiamide, buspirone). Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting. Further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. This review highlights the clinical presentation, diagnosis, mechanisms and treatment advancements for gastroparesis.

AB - Gastroparesis is defined by delayed gastric emptying (GE) and symptoms of nausea, vomiting, bloating, postprandial fullness, early satiety and abdominal pain. Most common aetiologies include diabetes, postsurgical and postinfectious, but in many cases it is idiopathic. Clinical presentation and natural history vary by the aetiology. There is significant morbidity and healthcare utilisation associated with gastroparesis. Mechanistic studies from diabetic animal models of delayed GE as well as human full-thickness biopsies have significantly advanced our understanding of this disorder. An innate immune dysregulation and injury to the interstitial cells of Cajal and other components of the enteric nervous system through paracrine and oxidative stress mediators is likely central to the pathogenesis of gastroparesis. Scintigraphy and 13C breath testing provide the most validated assessment of GE. The stagnant gastroparesis therapeutic landscape is likely to soon see significant changes. Relatively newer treatment strategies include antiemetics (aprepitant), prokinetics (prucalopride, relamorelin) and fundic relaxants (acotiamide, buspirone). Endoscopic pyloromyotomy appears promising over the short term, especially for symptoms of nausea and vomiting. Further controlled trials and identification of the appropriate subgroup with pyloric dysfunction and assessment of long-term outcomes are essential. This review highlights the clinical presentation, diagnosis, mechanisms and treatment advancements for gastroparesis.

KW - Gastric Emptying

KW - Gastroparesis

KW - Interstitial Cells of Cajal

KW - Macrophages

KW - Prokinetic Agent

UR - http://www.scopus.com/inward/record.url?scp=85072829196&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072829196&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2019-318712

DO - 10.1136/gutjnl-2019-318712

M3 - Article

C2 - 31563877

AN - SCOPUS:85072829196

JO - Gut

JF - Gut

SN - 0017-5749

ER -